The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Global epidemiology and genotype distribution of the hepatitis C virus infection
Open accessAbstract
The treatment of chronic hepatitis C virus (HCV) infection has the potential to change significantly over the next few years as therapeutic regimens are rapidly evolving. However, the burden of chronic infection has not been quantified at the global level using the most recent data. Updated estimates of HCV prevalence, viremia and genotypes are critical for developing strategies to manage or eliminate HCV infection. To achieve this, a comprehensive literature search was conducted for anti-HCV prevalence, viraemic prevalence and genotypes for all countries. Studies were included based on how well they could be extrapolated to the general population, sample size and the age of the study. Available country estimates were used to develop regional and global estimates. Eighty-seven countries reported anti-HCV prevalence, while HCV viraemic rates were available for fifty-four countries. Total global viraemic HCV infections were estimated at 80 (64-103) million infections. Genotype distribution was available for ninety-eight countries. Globally, genotype 1 (G1) was the most common (46%), followed by G3 (22%), G2 (13%), and G4 (13%). In conclusion, the total number of HCV infections reported here are lower than previous estimates. The exclusion of data from earlier studies conducted at the peak of the HCV epidemic, along with adjustments for reduced prevalence among children, are likely contributors. The results highlight the need for more robust surveillance studies to quantify the HCV disease burden more accurately.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Decisions with Multiple Objectives: Preferences and Value Tradeoffs.
Tsoukias, A., Keeney, R. L., & Raiffa, H. (1994) · The Journal of the Operational Research Society · doi:10.2307/2584151 · Cited by 8,370
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., & Wiersma, S. T. (2013) · Hepatology · doi:10.1002/hep.26141 · Cited by 2,515
Value-Focused Thinking: A Path to Creative Decisionmaking
Keeney, R. L. (1992) · Cited by 2,133
The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002
Armstrong, G. L., Wasley, A., Simard, E. P., McQuillan, G. M., Kuhnert, W. L., & Alter, M. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00004 · Cited by 1,955
Decisions with Multiple Objectives: Preferences and Value Trade-Offs
Keeney, R. L., Raiffa, H., & Rajala, D. W. (1979) · IEEE Transactions on Systems, Man, and Cybernetics · doi:10.1109/tsmc.1979.4310245 · Cited by 1,782
The global burden of hepatitis C
Lavanchy, D. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01934.x · Cited by 1,368
Evolving epidemiology of hepatitis C virus
Lavanchy, D. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03432.x · Cited by 1,318
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review
Mathers, B. M., Degenhardt, L., Phillips, B., Wiessing, L., Hickman, M., Strathdee, S. A., Wodak, A., Panda, S., Tyndall, M., Toufik, A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61311-2 · Cited by 1,285
Nelson, P. K., Mathers, B. M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., & Degenhardt, L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61097-0 · Cited by 1,267
Cited by
Blach, S., Zeuzem, S., Manns, M., Altraif, I., Duberg, A.-S., Muljono, D. H., Waked, I., Alavian, S. M., Lee, M.-H., Negro, F., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30181-9 · Cited by 2,006
Self-citationSofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Feld, J. J., Jacobson, I. M., Hézode, C., Asselah, T., Ruane, P. J., Gruener, N., Abergel, A., Mangia, A., Lai, C.-L., Chan, H. L. Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1512610 · Cited by 1,106
Ghany, M. G., Morgan, T. R., & Panel, A. H. C. G. (2020) · Hepatology · doi:10.1002/hep.31060 · Cited by 955
Petruzziello, A., Marigliano, S., Loquercio, G., Cozzolino, A., & Cacciapuoti, C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i34.7824 · Cited by 864
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Foster, G. R., Afdhal, N., Roberts, S. K., Bräu, N., Gane, E. J., Pianko, S., Lawitz, E., Thompson, A., Shiffman, M. L., Cooper, C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1512612 · Cited by 846
Bekker, L.-G., Alleyne, G., Baral, S., Cepeda, J., Daskalakis, D., Dowdy, D., Dybul, M., Eholie, S., Esom, K., Garnett, G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31070-5 · Cited by 763
Platt, L., Easterbrook, P., Gower, E., McDonald, B., Sabin, K., McGowan, C., Yanny, I., Razavi, H., & Vickerman, P. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00485-5 · Cited by 731
Self-citationBlach, S., Terrault, N. A., Tacke, F., Gamkrelidze, I., Craxi, A., Tanaka, J., Waked, I., Dore, G. J., Abbas, Z., Abdallah, A. R., et al. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00472-6 · Cited by 641
Self-citationAccelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
Cooke, G. S., Andrieux-Meyer, I., Applegate, T. L., Atun, R., Burry, J. R., Cheinquer, H., Dusheiko, G., Feld, J. J., Gore, C., Griswold, M. G., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30270-x · Cited by 535
Self-citationManns, M. P., Buti, M., Gane, E., Pawlotsky, J.-M., Razavi, H., Terrault, N., & Younossi, Z. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.6 · Cited by 506
Self-citationWorld‐wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma
de Martel, C., Maucort‐Boulch, D., Plummer, M., & Franceschi, S. (2015) · Hepatology · doi:10.1002/hep.27969 · Cited by 503
Razavi, H., Waked, I., Sarrazin, C., Myers, R. P., Idilman, R., Calinas, F., Vogel, W., Mendes Correa, M. C., Hézode, C., Lázaro, P., et al. (2014) · Journal of Viral Hepatitis · doi:10.1111/jvh.12248 · Cited by 477
Self-citationGlecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
Zeuzem, S., Foster, G. R., Wang, S., Asatryan, A., Gane, E., Feld, J. J., Asselah, T., Bourlière, M., Ruane, P. J., Wedemeyer, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1702417 · Cited by 439
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
Sarrazin, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.09.011 · Cited by 423
Barua, S., Greenwald, R., Grebely, J., Dore, G. J., Swan, T., & Taylor, L. E. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0406 · Cited by 401
Global epidemiology and burden of HCV infection and HCV-related disease
Thrift, A. P., El-Serag, H. B., & Kanwal, F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.176 · Cited by 382
Autophagy in liver diseases: A review
Qian, H., Chao, X., Williams, J., Fulte, S., Li, T., Yang, L., & Ding, W.-X. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.100973 · Cited by 373
Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., Jordan, A., Degenhardt, L., Hope, V., Hutchinson, S., et al. (2018) · Addiction · doi:10.1111/add.14012 · Cited by 362
Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide
Maucort‐Boulch, D., de Martel, C., Franceschi, S., & Plummer, M. (2018) · International Journal of Cancer · doi:10.1002/ijc.31280 · Cited by 358
Update on global epidemiology of viral hepatitis and preventive strategies
Jefferies, M., Rauff, B., Rashid, H., Lam, T., & Rafiq, S. (2018) · World Journal of Clinical Cases · doi:10.12998/wjcc.v6.i13.589 · Cited by 352
Forns, X., Lee, S. S., Valdes, J., Lens, S., Ghalib, R., Aguilar, H., Felizarta, F., Hassanein, T., Hinrichsen, H., Rincon, D., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30496-6 · Cited by 343
Disease Burden of Hepatocellular Carcinoma: A Global Perspective
Sayiner, M., Golabi, P., & Younossi, Z. M. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05537-2 · Cited by 339
From non-A, non-B hepatitis to hepatitis C virus cure
Pawlotsky, J.-M., Feld, J. J., Zeuzem, S., & Hoofnagle, J. H. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.006 · Cited by 328
Borgia, S. M., Hedskog, C., Parhy, B., Hyland, R. H., Stamm, L. M., Brainard, D. M., Subramanian, M. G., McHutchison, J. G., Mo, H., Svarovskaia, E., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy401 · Cited by 312
Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., Jordan, A., Degenhardt, L., Hope, V., Hutchinson, S., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012021.pub2 · Cited by 305
Rockstroh, J. K., Nelson, M., Katlama, C., Lalezari, J., Mallolas, J., Bloch, M., Matthews, G. V., Saag, M. S., Zamor, P. J., Orkin, C., et al. (2015) · The Lancet HIV · doi:10.1016/s2352-3018(15)00114-9 · Cited by 305
Kwo, P. Y., Poordad, F., Asatryan, A., Wang, S., Wyles, D. L., Hassanein, T., Felizarta, F., Sulkowski, M. S., Gane, E., Maliakkal, B., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.039 · Cited by 302
Lawitz, E., Gane, E., Pearlman, B., Tam, E., Ghesquiere, W., Guyader, D., Alric, L., Bronowicki, J.-P., Lester, L., Sievert, W., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61795-5 · Cited by 299
Kandeel, A., Genedy, M., El‐Refai, S., Funk, A. L., Fontanet, A., & Talaat, M. (2017) · Liver International · doi:10.1111/liv.13186 · Cited by 283
Sulkowski, M., Hezode, C., Gerstoft, J., Vierling, J. M., Mallolas, J., Pol, S., Kugelmas, M., Murillo, A., Weis, N., Nahass, R., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61793-1 · Cited by 280
Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors
Baecker, A., Liu, X., La Vecchia, C., & Zhang, Z.-F. (2018) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000428 · Cited by 275
Hézode, C., Asselah, T., Reddy, K. R., Hassanein, T., Berenguer, M., Fleischer-Stepniewska, K., Marcellin, P., Hall, C., Schnell, G., Pilot-Matias, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60159-3 · Cited by 259
Iyengar, S., Tay-Teo, K., Vogler, S., Beyer, P., Wiktor, S., de Joncheere, K., & Hill, S. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002032 · Cited by 255
Sexual transmission of hepatitis C virus among gay and bisexual men: a systematic review.
Jin, F., Matthews, G. V., & Grulich, A. E. (2017) · Sexual Health · doi:10.1071/sh16141 · Cited by 74
Zanone, M. M., Marinucci, C., Ciancio, A., Cocito, D., Zardo, F., Spagone, E., Ferrero, B., Cerruti, C., Charrier, L., Cavallo, F., et al. (2021) · Liver International · doi:10.1111/liv.15002 · Cited by 19
Influence of the inflammatory response on treatment of hepatitis C with triple therapy
Winckler, F. C., Braz, A. M. M., Silva, V. N. D., Golim, M. D. A., Andrade, V. G. D., Machado, P. E. D. A., Silveira, L. V. D. A., & Silva, G. F. (2018) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/0037-8682-0137-2018 · Cited by 2
Metadata
- Authors
- Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., & Razavi, H.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 61
- Issue
- 1
- Pages
- S45-S57
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2042063943
- Cited by
- 1,903
- References
- 107
- FWCI
- 118.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.